University of East Anglia
Also known as: Clinical Professor, Norwich Medical School, The University of East Anglia, UK | Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) | Clinical Senior Lecturer, University of East Anglia | Dean of Medicine, Norwich Medical School, The University of East Anglia, UK | Department of Nutrition, University of East Anglia, Norwich, U.K. | Emily Woodhouse | James Paget Hospital | James Paget University Hospital NHS Foundation Trust | Julie Dawson | Norfolk and Norwich University Hospitals NHS Foundation Trust | Norwich Clinical Trials Unit | Norwich Medical School | Norwich Medical School; Chaire of DaRe2THINK Independent DMC | School of Health Sciences, University of East Anglia | The Bertram Diabetes Centre & Radiology department (Norfolk & Norwich University Hospital, UK) | UEA | University of East Anglia
Highest phase reached
Phase 4
First clinical trial
May 1, 2001Last known activity
Dec 1, 2025
Timeline
1960s
- Jan 1, 1963
University of East Anglia— Founded
Drugs by trial phase (55 distinct, 56 trials)
Phase 4 (5 own, 0 via acquisition)
Phase 3 (14 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (26 own, 0 via acquisition)
Indications
Studied for
- Aneurysm
- Asthma
- Atherosclerosis
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Cardiovascular Diseases
- Cataract
- Connective Tissue Diseases
- Coronary Artery Disease
- Dementia
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dilatation, Pathologic
- Dyslipidemias
- Emphysema
- Fractures, Bone
- Fractures, Stress
- Glaucoma
- Glaucoma, Open-Angle
- Gout
- Heart Diseases
- Hemorrhoids
- Hypertrophy
- Hypoxia
- Kidney Diseases
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Diseases, Obstructive
- Macular Edema
- Mixed Connective Tissue Disease
- Multiple Sclerosis
- Muscle Spasticity
- Myositis
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Emphysema
- Renal Insufficiency, Chronic
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Vascular Diseases
Recent trials (50)
- NCT07255755Lead sponsorN/ADec 1, 2025
- NCT07255755OfficialN/ADec 1, 2025
- NCT06715449Lead sponsorPhase 2/Phase 3Nov 22, 2024
- NCT06551961CollaboratorN/AAug 9, 2024
- NCT06469645OfficialPhase 2/Phase 3May 30, 2024
- NCT06469645Lead sponsorPhase 2/Phase 3May 30, 2024
- NCT06469645CollaboratorPhase 2/Phase 3May 30, 2024
- NCT06262711OfficialN/AFeb 29, 2024
- NCT06262711Lead sponsorN/AFeb 29, 2024
- NCT06551948CollaboratorN/AJan 1, 2024
- NCT05772013CollaboratorPhase 4May 31, 2023
- NCT06502535CollaboratorN/AMay 9, 2023
- NCT05911347CollaboratorN/AMay 9, 2023
- NCT05584007CollaboratorPhase 3Mar 1, 2023
- NCT05584007CollaboratorPhase 3Mar 1, 2023
Details
- Founded
- Norwich, GB Jan 1, 1963
- Last known activity
- Dec 1, 2025